Renal damage after myocardial infarction is prevented by renin-angiotensin-aldosterone-system intervention

Journal of the American Society of Nephrology

Volumn 17, Issue 11, 2006, Pages 3059-3066

  Windt, Willemijn A K M ^a   Eijkelkamp, Wouter B A ^a   Henning, Robert H ^a   Kluppel, Alex C A ^a   De Graeff, Pieter A ^a   Hillege, Hans L ^a   Schäfer, Stefan ^b,c   De Zeeuw, Dick ^a   Van Dokkum, Richard P E ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^b SANOFI AVENTIS DEUTSCHLAND GMBH   (Germany)

^c BAYER PHARMA AG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA SMOOTH MUSCLE ACTIN; AVE 7688; DIPEPTIDYL CARBOXYPEPTIDASE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; LISINOPRIL; UNCLASSIFIED DRUG; VASOPEPTIDASE INHIBITOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME INHIBITION; FOCAL GLOMERULOSCLEROSIS; HEART INFARCTION; KIDNEY INJURY; MALE; NEPHRECTOMY; NONHUMAN; PRIORITY JOURNAL; PROTEINURIA; RAT; RENAL PROTECTION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; STAINING; SYSTOLIC BLOOD PRESSURE;

EID: 33750738568     PISSN: 10466673     EISSN: None     Source Type: Journal    
DOI: 10.1681/ASN.2006030209     Document Type: Article

References (36)

1. Mann JF, Gerstein HC, Pogue J, Bosch J, Yusuf S: Renal insufficiency as a predictor of cardiovascular outcomes and the impact of ramipril: The HOPE randomized trial. Ann Intern Med 134: 629-636, 2001
2. Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY: Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med 351: 1296-1305, 2004
3. Henry RM, Kostense PJ, Bos G, Dekker JM, Nijpels G, Heine RJ, Bouter LM, Stehouwer CD: Mild renal insufficiency is associated with increased cardiovascular mortality: The Hoorn Study. Kidney Int 62: 1402-1407, 2002
4. Hillege HL, Janssen WM, Bak AA, Diercks GF, Grobbee DE, Crijns HJ, Van Gilst WH, de Zeeuw D, De Jong PE: Microalbuminuria is common, also in a nondiabetic, non-hypertensive population, and an independent indicator of cardiovascular risk factors and cardiovascular morbidity. J Intern Med 249: 519-526, 2001
5. Hillege HL, Fidler V, Diercks GF, van Gilst WH, De Zeeuw D, van Veldhuisen DJ, Gans RO, Janssen WM, Grobbee DE, De Jong PE: Urinary albumin excretion predicts cardiovascular and noncardiovascular mortality in general population. Circulation 106: 1777-1782, 2002
6. Janssen WM, Hillege H, Pinto-Sietsma SJ, Bak AA, de Zeeuw D, De Jong PE: Low levels of urinary albumin excretion are associated with cardiovascular risk factors in the general population. Clin Chem Lab Med 38: 1107-1110, 2000
7. de Zeeuw D, Remuzzi G, Parving HH, Keane WF, Zhang Z, Shahinfar S, Snapinn S, Cooper ME, Mitch WE, Brenner BM: Albuminuria, a therapeutic target for cardiovascular protection in type 2 diabetic patients with nephropathy. Circulation 110: 921-927, 2004
8. Anavekar NS, McMurray JJ, Velazquez EJ, Solomon SD, Kober L, Rouleau JL, White HD, Nordlander R, Maggioni A, Dickstein K, Zelenkofske S, Leimberger JD, Califf RM, Pfeffer MA: Relation between renal dysfunction and cardiovascular outcomes after myocardial infarction. N Engl J Med 351: 1285-1295, 2004
9. Raine AE, Seymour AM, Roberts AF, Radda GK, Ledingham JG: Impairment of cardiac function and energetics in experimental renal failure. J Clin Invest 92: 2934-2940, 1993
10. Amann K, Tyralla K, Gross ML, Schwarz U, Tornig J, Haas CS, Ritz E, Mall G: Cardiomyocyte loss in experimental renal failure: Prevention by ramipril. Kidney Int 63: 1708-1713, 2003
11. van Dokkum RP, Eijkelkamp WB, Kluppel AC, Henning RH, van Goor H, Citgez M, Windt WA, van Veldhuisen DJ, de Graeff PA, de Zeeuw D: Myocardial infarction enhances progressive renal damage in an experimental model for cardiorenal interaction. J Am Soc Nephrol 15: 3103-3110, 2004
12. Duncan AM, James GM, Anastasopoulos F, Kladis A, Briscoe TA, Campbell DJ: Interaction between neutral endopeptidase and angiotensin converting enzyme inhibition in rats with myocardial infarction: Effects on cardiac hypertrophy and angiotensin and bradykinin peptide levels. J Pharmacol Exp Ther 289: 295-303, 1999
13. Jandeleit-Dahm K, Burrell LM, Kanazawa M, Casley D, Jackson B, Johnston CI: Effects of neutral endopeptidase inhibition in the rat remnant kidney model. Kidney Blood Press Res 21: 419-424, 1998
14. Martin FL, Stevens TL, Cataliotti A, Schirger JA, Borgeson DD, Redfield MM, Luchner A, Burnett JC Jr: Natriuretic and antialdosterone actions of chronic oral NEP inhibition during progressive congestive heart failure. Kidney Int 67: 1723-1730, 2005
15. Corti R, Burnett JC Jr, Rouleau JL, Ruschitzka F, Luscher TF: Vasopeptidase inhibitors: A new therapeutic concept in cardiovascular disease? Circulation 104: 1856-1862, 2001
16. Weber MA: Vasopeptidase inhibitors. Lancet 358: 1525-1532, 2001
17. Campbell DJ: Vasopeptidase inhibition: A double-edged sword? Hypertension 41: 383-389, 2003
18. Taal MW, Nenov VD, Wong W, Satyal SR, Sakharova O, Choi JH, Troy JL, Brenner BM: Vasopeptidase inhibition affords greater renoprotection than angiotensin-converting enzyme inhibition alone. J Am Soc Nephrol 12: 2051-2059, 2001
19. Cao Z, Burrell LM, Tikkanen I, Bonnet F, Cooper ME, Gilbert RE: Vasopeptidase inhibition attenuates the progression of renal injury in subtotal nephrectomized rats. Kidney Int 60: 715-721, 2001
20. Benigni A, Zoja C, Zatelli C, Corna D, Longaretti L, Rottoli D, Maggioni P, Todeschini M, Noris M, Remuzzi G: Vasopeptidase inhibitor restores the balance of vasoactive hormones in progressive nephropathy. Kidney Int 66: 1959-1965, 2004
21. Schafer S, Linz W, Bube A, Gerl M, Huber J, Kurzel GU, Bleich M, Schmidts HL, Busch AE, Kutten H: Vasopeptidase inhibition prevents nephropathy in Zucker diabetic fatty rats. Cardiovasc Res 60: 447-454, 2003
22. Schafer S, Linz W, Vollert H, Biemer-Daub G, Rutten H, Bleich M, Busch AE: The vasopeptidase inhibitor AVE7688 ameliorates type 2 diabetic nephropathy. Diabetologia 47: 98-103, 2004
23. Schafer S, Schmidts HL, Bleich M, Busch AE, Linz W: Nephroprotection in Zucker diabetic fatty rats by vasopeptidase inhibition is partly bradykinin B2 receptor dependent. Br J Pharmacol 143: 27-32, 2004
24. Schoemaker RG, Debets JJ, Struyker-Boudier HA, Smits JF: Delayed but not immediate captopril therapy improves cardiac function in conscious rats, following myocardial infarction. J Mol Cell Cardiol 23: 187-197, 1991
25. Cushman DW, Cheung HS: Concentrations of angiotensin-converting enzyme in tissues of the rat. Biochim Biophys Acta 250: 261-265, 1971
26. Raij L, Azar S, Keane W: Mesangial immune injury, hypertension, and progressive glomerular damage in Dahl rats. Kidney Int 26: 137-143, 1984
27. Bongartz LG, Cramer MJ, Doevendans PA, Joles JA, Braam B: The severe cardiorenal syndrome: 'Guyton revisited.' Eur Heart J 26: 11-17, 2005
28. Swedberg K, Eneroth P, Kjekshus J, Wilhelmsen L: Hormones regulating cardiovascular function in patients with severe congestive heart failure and their relation to mortality. CONSENSUS Trial Study Group. Circulation 82: 1730-1736, 1990
29. Remuzzi G, Perico N, Macia M, Ruggenenti P: The role of renin-angiotensin-aldosterone system in the progression of chronic kidney disease. Kidney Int Suppl 99: S57-S65, 2005
30. Chiurchiu C, Remuzzi G, Ruggenenti P: Angiotensin-converting enzyme inhibition and renal protection in non-diabetic patients: The data of the meta-analyses. J Am Soc Nephrol 16[Suppl 1]: S58-S63, 2005
31. Boos CJ: Cardiovascular protection with ace inhibitors: More HOPE for EUROPA? Med Sci Monit 10: SR23-SR28, 2004
32. Levin ER, Gardner DG, Samson WK: Natriuretic peptides. N Engl J Med 339: 321-328, 1998
33. Shankland SJ: The podocyte's response to injury: Role in proteinuria and glomerulosclerosis. Kidney Int 69: 2131-2147, 2006
34. Rouleau JL, Pfeffer MA, Stewart DJ, Isaac D, Sestier F, Kerut EK, Porter CB, Proulx G, Qian C, Block AJ: Comparison of vasopeptidase inhibitor, omapatrilat, and lisinopril on exercise tolerance and morbidity in patients with heart failure: IMPRESS randomised trial. Lancet 356: 615-620, 2000
35. Lee DS, Tu JV, Juurlink DN, Alter DA, Ko DT, Austin PC, Chong A, Stukel TA, Levy D, Laupacis A: Risk-treatment mismatch in the pharmacotherapy of heart failure. JAMA 294: 1240-1247, 2005
36. Ezekowitz J, McAlister FA, Humphries KH, Norris CM, Tonelli M, Ghali WA, Knudtson ML: The association among renal insufficiency, pharmacotherapy, and outcomes in 6,427 patients with heart failure and coronary artery disease. J Am Coll Cardiol 44: 1587-1592, 2004